Consumer healthcare company Haleon (LSE: HLN) saw its shares rise over 5% on Thursday morning after reporting full-year revenue growth despite currency headwinds and disposals.
Haleon’s revenue for 2023 reached £11.30 billion, an 8.0% increase organically, although foreign exchange effects shaved off £416 million. The company also proposed a higher annual dividend of 6.0p compared to 2.4p in 2022 and narrowed its net debt to £8.51 billion.
Read More News:
Drax profits soar despite windfall tax, shares jump 6.6%
Looking ahead, Haleon anticipates further portfolio optimization and expects organic revenue growth of 4-6% in 2024, with operating profit growth exceeding revenue growth. Despite a challenging economic environment, the company remains confident in its ability to deliver on its guidance and achieve long-term success.
